“Unlocking the Power of REC-994: Exciting Phase 2 Results Revealed at International Stroke Conference!”
Sympathy for those affected by Cerebral Cavernous Malformations (CCM) Breaking News: Recursion reports positive data from Phase 2 study of REC-994 SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) recently revealed the 12-month data from the Phase 2 study (SYCAMORE) of REC-994, marking a significant milestone in the treatment of Cerebral…